1 results match your criteria: "AUA College of Medicine and Manipal Academy of Higher Education[Affiliation]"
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.
Indian J Pharmacol
October 2018
Department of Medical Pharmacology, AUA College of Medicine and Manipal Academy of Higher Education, Antigua, West Indies.
Objective: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen.
Patients And Methods: A prospective, open-label, nonrandomized study was conducted at the Department of Oncology.